WO1999028308A1 - Antibiotics and process for preparation - Google Patents
Antibiotics and process for preparation Download PDFInfo
- Publication number
- WO1999028308A1 WO1999028308A1 PCT/US1997/022012 US9722012W WO9928308A1 WO 1999028308 A1 WO1999028308 A1 WO 1999028308A1 US 9722012 W US9722012 W US 9722012W WO 9928308 A1 WO9928308 A1 WO 9928308A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- reaction product
- penicillin
- antibiotic
- cephalosporin
- group
- Prior art date
Links
- 0 CC([C@](CC1S*=N)N2C1C(O)=O)C2=O Chemical compound CC([C@](CC1S*=N)N2C1C(O)=O)C2=O 0.000 description 9
- SNUODSWXGWNMEE-CWJHNBGESA-N CCCC(C1OC1[C@H](C)C1)C(CC)[N]1(C)C(C)(C)CC Chemical compound CCCC(C1OC1[C@H](C)C1)C(CC)[N]1(C)C(C)(C)CC SNUODSWXGWNMEE-CWJHNBGESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
Definitions
- This invention is concerned with the preparation of a wide variety of antibiotics of new and novel structure and antimicrobial activity.
- the compounds thus prepared are products from the linking of diverse antibiotic moieties via difiinctional organic compounds such as diisocyanates, dianhydrides, diacidchlorides, diepoxides and carbodumides, said antibiotics being drawn from the classes of compounds sulfonamides, penicillins and related, cephalosporins and related, quinolones, chloramphenicol, erythromycins, metronidazole, tetracyclines and aminoglycocides.
- antimicrobial agents are classified as noted above, and there are many classes in addition to the above-noted ones.
- This invention is concerned with simple methods of preparing a large number of new and novel structures possessing a wide range of antibiotic activity via linking together two antibiotic moieties.
- A has the structure drawn from the following classes of antibiotics:
- aminoglycosides and B drawn from the same classes.
- L is drawn from a group of difunctional linking reagents.
- R is a variety of substituents.
- the sulfonamides listed below are of particular interest:
- R 3 and R ⁇ are a variety of substituents.
- the cephalosporins listed below are of particular interest.
- R 5 is a variety of substituents and the quinoline neucleus contains fluoro atom substitution.
- the quinolones listed below are of particular interest.
- the linking reagents are drawn from the type listed below.
- Y can be aliphatic, alicyciic, aromatic and heterocyclic groups. The particular formulas for each type are listed below.
- the five linking reagents are: diisocyanates, dianhydrides, diacidchlorides, diepoxides and carbodumides.
- antibiotics that can be linked are sulfonamides, trimethoprim, penicillins and related structures, cephalosporins and related structures, chloramphenicol, erythromycin, metronidazole, quinolones, tetracyclines and aminoglycosides.
- Diisocyanates can react with all acid groups, all hydroxyl groups and all primary and secondary amino groups.
- any antibiotic moiety, A containing a carboxylic acid, hydroxyl or amine function
- a A can be linked to any other antibiotic moiety B containing a carboxylic acid, hydroxyl or amine function.
- the diisocyanate can be used to link with an antibiotic moiety containing a single reactive group, as A and B above, or with an antibiotic moiety containing two functional groups as D, carboxylic acid and amine.
- the diisocyanate can be used to link any two antibiotics containing at least one carboxylic acid, alcohol or amino functional group, and will also effect linkage when each antibiotic moiety contains a plurality of groups.
- Dianhydrides can be employed to link a wide variety of antibiotic moieties containing hydroxy or primary or secondary amines. The reagent will also link antibiotic molecules where each antibiotic moiety contains a plurality of hydroxy, primary and secondary amine functional groups.
- Diacidchlorides can be employed to link a wide variety of antibiotic moieties containing hydroxyl and primary or secondary amine functional groups, and also where each moiety contains a plurality of said functions.
- Diepoxides can be utilized to link a very wide variety of antibiotic moieties where each contains carboxylic acid, alcohol, and primary or secondary amine functional groups, or a plurality of such groups.
- Carbodumides can be utilized to link a wide variety of antibiotic moieties where each moiety contains at least one of the following functional groups: carboxylic acid, alcohol, and primary or secondary amine. This reagent differs from the four previously discussed since the reagent bonds the two antibiotic moieties via the removal of the elements of water from the functional groups.
- Moieties containing carboxylic acid groups can be linked with moieties containing carboxylic acid groups to form anhydrides.
- Moieties containing carboxylic acid groups can be linked to moieties containing alcohols or primary or secondary amines to form esters or amides.
- Moieties containing hydroxyl groups can be linked to moieties containing hydroxyl or primary or secondary amine groups to form ethers or substituted amines. Where pluralities of the carboxylic acid, hydroxyl or amine functional groups are contained in one or both antibiotic moieties, linkage will occur but the products may be complex and require chromatographic separation.
- the present invention describes methods for making a number of linked antibiotic molecules.
- the linked antibiotics are to be utilized in treating various infections in man and animals, without undue adverse side effects such as toxicity, inflammation and allergies.
- to-be linked compounds There are several groups of these to-be linked compounds which can be enumerated: sulfonamides, penicillins, cephalosporins, quinolones, chloramphenicol, erythryomycin, metronidazole, tetracyclines and aminoglycosides. With each case, the antibiotics to be linked will be taken two at a time from the above groups, thus:
- Aminoglycosides A streptomycin
- linking agents that will be used to link the antibiotic moities are drawn from several classes of organic molecules:
- linking of two antibiotic moieties depends upon the presence of the following groups: carboxyl, amino and hydroxyl and requires a minimum total of two such groups, but with a further plurality may also be utilized.
- the possible combinations of the three reactive groups are five.
- the amide product is easily separated from the by-product dicyclo- hexylurea by crystallization or liquid chromatography techniques.
- the linking rules are as follows:
- Diisocyanates can react with all acid carboxyl groups, all hydroxyl groups and all primary and secondary amino groups.
- any antibiotic moiety containing a carboxylic acid group, a hydroxyl group or an amine group can be linked to any other antibiotic moiety also containing a carboxylic acid group, hydroxyl or amine function.
- a single antibiotic moiety contains a plurality of groups, as a carboxyl group and a hydroxyl group, or a carboxyl group and an amino group
- this moiety can be linked by reaction with a diisocyanate to a second antibiotic moiety containing a plurality of groups, as a carboxyl group and a hydroxyl group, or a carboxyl group and an amino group.
- the diisocyanate reagent can be used to link any two antibiotic moieties each containing at least one carboxylic acid, alcohol or amino functional group, and can also be used when each antibiotic contains a plurality of said groups.
- Dianhydrides can be utilized to link a wide variety of antibiotic moitieties in which each moiety contains at least one hydroxyl or primary or secondary amine group.
- the dianhydride reagent can also be utilized to link antibiotic moities in which each moiety contains a multiplicity of hydroxyl or amino groups. In cases involving the linking of antibiotic moities containing a multiplicity of groups, a mix of products will be realized but can be separated easily via chromatographic techniques.
- Diacidchlorides as a linking agent are covered by rules identical to those for dianhydrides.
- Diacidchlorides can be used to link a wide variety of antibiotic moieties in which each moiety contains at least one hydroxyl or amino group.
- the aciddichloride reagent can also be used to link antibiotic moieties where each moiety contains a multiplicity of hydroxyl or and amino groups. In cases involving a multiplicity of groups, a mixture of products will be realized which can be separated easily via chromatographic techniques.
- Diepoxides as linking agents can be used to link antibiotic moities where each moiety contains a carboxyl, hydroxyl, or amino group, or where each moiety contains a plurality of said groups.
- Diepoxides possessing a plurality of such groups react with the epoxy linking agents a complex mix of products will be formed which can be separated via chromatographic techniques.
- Carbodumides as linking agents can be utilized to link a very large number of antibiotic types. Antibiotic moieties in which each moiety contains a single carboxyl group yield anhydrides. Antibiotic moities in which one moiety contains a carboxyl group only will react with a moiety containing a single hydroxyl group to form a single ester. Antibiotic moieties containing a plurality of carboxyl and hydroxyl groups will form a complex mixture of esters when reacted with carbodumides. Antibiotic moieties containing a single carboxyl group will react with antibiotic moieties containing a single amino group to form a single product containing an amide group.
- antibiotic moieties containing a multiplicity of carboxyl, hydroxyl and amino groups are linked via carbodumides, a mixture of esters and amides will be formed.
- antibiotic moieties containing singular hydroxyl groups or a multiplicity of hydroxyl groups are linked, the products will be singular or multicomponent ethers.
- the linking of antibiotic moieties containing singular or multiple hydroxyl and amino groups leads to the formation of a single substituted amine, or a multiplicity of amines. All of the mixtures generated by the above said reactions can be separated via chromatographic techniques.
- Evaluation apply to streaked plate of several cultures ⁇ E. coli, Strep. Group A, P. aruginosa Equipment 250 ml round bottom 3-neck flask equipped with glascol mantle for heating, thermometer, reflux condenser and teflon stirring bar energized by magnetic stirring.
- reaction time may be as short as 1 hour.
- IR monitor is via carbodiimide band at 4.50 ⁇ .
- the dry pyridine solvent 50 ml., is placed in the 250 ml round bottom flask and 1.72 g. (0.01 mole) of p-aminobenzenesulfonamide and 1.68 g. (0.01 mole) of hexyldiisocyanate is added, the temperature raised to 40°C by means of the variac controlling the heating of the glascol mantle. The heating and stirring are continued for 4 hours, and at the end of each hour a small sample is withdrawn from the flask by means of a pippette and examined by means of IR sectroscopy.
- the IR spectrocopy scan is determined from 2.5 microns to 15.0 microns, and the concentration of diisocyanate is determined from the intensity of the absorption band at 4.45 microns, a band due to the -NCO group.
- a steady drop in the concentration of the -NCO group indicates progress of the reaction.
- the concentration of the isocyanate group has dropped by 80 per cent.
- the reaction is forced to conclusion by raising the temperature to 50°C for two hours, at the end of which time the -NCO group is not detectable by IR spectroscopy.
- the reaction is terminated by the addition of 50 ml of water and the precipitated reaction product dried in a vacuum oven at 25°C for 2 hours to yield 3.0 g., 8.8 per cent.
- the product was evaluated for biological activity via applying a 1 per cent solution in pyridine to TLC (thin layer chromatography) plates.
- the developing solvent used was a 10-90 mixture of acetone and methanol, and the progress was monitored by a UV light.
- the spots on the chromatogram were evaluated via mechanical removal and the absorbent was separated from the product fraction by dissolving in pyridine, and the pyridine solution was dried onto filter paper. Tabs of the filter paper were applied to ager culture plates streaked with standard bacterial cultures of S. aureus, E. coli and P aureginosa. Standard antibiotics, as p-aminosulfonamide and penicillins were used for comparison. All products showed modest inhibition zones in the vicinity of the filter paper tabs containing the product fractions.
Abstract
A group of reagents, as diisocyanates, dianhydrides, diacidchlorides, diepoxides, carbodiimides and the like are utilized to link a wide variety of antibiotic moieties, reacted two at a time with said reagents, the said antibiotic moieties containing groups reactive with the linking reagents as carboxylic acid, alcohol, primary amine, and secondary amine functional groups, said functional groups being present as singularities or as multiplicities, products being readily purified using chromatographic techniques, and said products of above reactions being valuable for the treatment of microbial infections of man and animals.
Description
ANTIBIOTICS AND PROCESS FOR PREPARATION
FIELD OF THE INVENTION
This invention is concerned with the preparation of a wide variety of antibiotics of new and novel structure and antimicrobial activity. The compounds thus prepared are products from the linking of diverse antibiotic moieties via difiinctional organic compounds such as diisocyanates, dianhydrides, diacidchlorides, diepoxides and carbodumides, said antibiotics being drawn from the classes of compounds sulfonamides, penicillins and related, cephalosporins and related, quinolones, chloramphenicol, erythromycins, metronidazole, tetracyclines and aminoglycocides.
BACKGROUND OF THE INVENTION
The medical literature regarding antimicrobial agents is vast and describes a number of antimicrobials including naturally occurring compounds as well as synthetic or semisynthetic compounds produced in the organic laboratory. These antimicrobial agents are classified as noted above, and there are many classes in addition to the above-noted ones.
It has been realized that the linking of two antibiotic moieties functioning in different fashions, as for example inhibiting cell-wall synthesis or protein synthesis or DNA synthesis, can be of value. Two antibiotic moieties can also be linked in which one is known to attack Gram positive bacteria and another to attack Gram negative bacteria, and this new entity is of value.
Usually the synthesis of linked antibiotics requires an extended set of organic laboratory procedures in which prior to the linkage of diverse types, such as quinolones and lactams, certain groups in the molecule must be blocked, the blocked entity then linked to a second antibiotic, which may also require blocking of some functional groups, and also the blocking groups require removal. It has been found surprisingly that a number of difunctional reagents can effect an efficient linkage of very diverse antibiotic structures. Further, the progress of the reaction can easily be followed via IR spectroscopy techniques, and the isolation of meaningful quantities achieved in facile fashion via liquid chromatography techniques.
SUMMARY OF THE IN ENTION
This invention is concerned with simple methods of preparing a large number of new and novel structures possessing a wide range of antibiotic activity via linking together two antibiotic moieties.
A - L - B
wherein A has the structure drawn from the following classes of antibiotics:
1. sulfonamides and related
2. penicillins and related
3. cephalosporins and related
4. quinolones
5. chloramphenicol
6. erythromycin
7. metronidazole
8. tetracyclines
9. aminoglycosides and B, drawn from the same classes.
The classes may be further characterized by the following general formulas and particular examples. L is drawn from a group of difunctional linking reagents.
1. Sulfonamides and Related
where R is a variety of substituents. The sulfonamides listed below are of particular interest:
A. p-aminobenzenesulfonamide
B. sulfamethoxyazole
C. acetylsulfoxazole
D. sulfamethoxypyridazine
E. sulfadiazine
2. Penicillins and Related
n where R is a variety of substituents. The penicillins listed below are of particulai : interest.
A. benzyl penicillin
B. procaine penicillin G
C. phenoxymethyl penicillin
D. ampicillin
E. amoxycillin
F. methicillin
G. oxacillin
H. cloxacillin
I. dicloxacillin
J. flucloxacillin
K. nafcillin
L. carbenicillin
M. ticaricillin
N. talampicillin
0. becampicillin
P. pivampicillin
Q. penamcarboxyli ic acid
R. hydroxyethyl penem
S. imipenem
T. amdinocilin
3. CephalosDorins and Related:
where R3 and R^ are a variety of substituents. The cephalosporins listed below are of particular interest.
A. cephalosporin C
B. cephalothin
C. cephaloridine
D. cephradine
E. cephazolin
F. cephalexin
G. cefadroxil H. cefaclor
I. cephamandole J. cefuroxine K. cefotaxime L. ceftizoxime M. ceftazidime N. cefoperazone O. cephamycin C P. cefoxitin Q. moxalactam
4. Quinolones
where R5 is a variety of substituents and the quinoline neucleus contains fluoro atom substitution. The quinolones listed below are of particular interest.
A. nalidixic acid
B. norfloxacin
C. enoxacin
D. ciprofloxacin
E. ofloxacin
5. Chloramphenicol
6. Ervthromvcin
7. Metronidazole
8. Tetracvclines
where the general formula given above is substituted to yield the particular compounds listed below.
A. tetracycline
B. oxytetracycline
C. chlortetracycline
D. rolitetracycline
E. methacycline
F. doxycycline
G. demeclocycline H. sancycline
I. lymecycline J. clomocycline K. minocycline
9. Aminoglvcosides
Streptomycin (R - CH,NH)
The general formula above is variously substituted to give the particular isomers listed below.
A. streptomycin
B. tobramycin C kanamycin
D. amikacin
E. gentamicin Cl
F. nitilimicin
G. neomycin
H. paromomycin I. spectinomycin
The linking reagents are drawn from the type listed below. Diisocyanates NCO - Y - NCO
Diianhydrides
Diacidchlorides O O
I I I I
Cl - C - Y - C - Cl
✓°\ /°\
Diepoxides CH2 - CH - Y - CH - CH2
Carbodumides Y - N = C = N - Y
In the above general formulas Y can be aliphatic, alicyciic, aromatic and heterocyclic groups. The particular formulas for each type are listed below. Diisocyanates:
1 ,6-hexamethylenediisocyanate
2,4-tolyldiisocyanate
2,6-tolyldiisocyanate
4,4'-methylene bis phenylisocyanate
4,4-isopropylidene bis phenylisocyanate
1 ,4-phenyldiisothiocyanate
1 ,4-phenyldiisocyanate
Dianhydrides pyromellitic dianhydride bis maleic dianhydride
3,3,4,4'-benzophenonetetracarboxylic dianhydride 1,2,6,7- hexanetetracarboxylic dianhydride 1,2,4,5- naphthalenetetracarboxylic dianhydride
Diacidchlorides terphthaloyl chloride isophthaloyl chloride phthaloyl chloride adipolyl chloride glutaryl chloride
Diepoxides 1,3-butane diepoxide 1,5-cyclooctatetraene diepoxide vinylcyclohexene diepoxide 1,4-divinylbenzene diepoxide
Carbodumides dicyclohexylcarbodiimide ditolylcarbodiimide
Rules Based on Linking Agents
Surprisingly only a few rules must be obeyed to take advantage of five different linking reagents applicable to linking two antibiotic molecules. The five linking reagents are: diisocyanates, dianhydrides, diacidchlorides, diepoxides and carbodumides.
The types of antibiotics that can be linked are sulfonamides, trimethoprim, penicillins and related structures, cephalosporins and related structures, chloramphenicol, erythromycin, metronidazole, quinolones, tetracyclines and aminoglycosides.
The linking rules are as follows: 1. Diisocyanates can react with all acid groups, all hydroxyl groups and all primary and secondary amino groups. Thus any antibiotic moiety, A, containing a carboxylic acid, hydroxyl or amine function
COOH OH NH
/ X 7 i A A
can be linked to any other antibiotic moiety B containing a carboxylic acid, hydroxyl or amine function.
COOH OH NH
/ / /
B B B
When a single antibiotic moiety contains more than a single functional group, as C,
the diisocyanate can be used to link with an antibiotic moiety containing a single reactive group, as A and B above, or with an antibiotic moiety containing two functional groups as D, carboxylic acid and amine.
COOH D
NH
When a diisocyanate is used to link antibiotic moieties containing a plurality of groups, a mixture of products will be realized, but with chromatographic techniques the mixtures are easily separated.
Summarizing, the diisocyanate can be used to link any two antibiotics containing at least one carboxylic acid, alcohol or amino functional group, and will also effect linkage when each antibiotic moiety contains a plurality of groups.
2. Dianhydrides can be employed to link a wide variety of antibiotic moieties containing hydroxy or primary or secondary amines. The reagent will also link antibiotic molecules where each antibiotic moiety contains a plurality of hydroxy, primary and secondary amine functional groups.
3. Diacidchlorides can be employed to link a wide variety of antibiotic moieties containing hydroxyl and primary or secondary amine functional groups, and also where each moiety contains a plurality of said functions.
4. Diepoxides can be utilized to link a very wide variety of antibiotic moieties where each contains carboxylic acid, alcohol, and primary or secondary amine functional groups, or a plurality of such groups.
5. Carbodumides can be utilized to link a wide variety of antibiotic moieties where each moiety contains at least one of the following functional groups: carboxylic acid, alcohol, and primary or secondary amine. This reagent differs from the four previously discussed since the reagent bonds the two antibiotic moieties via the removal of the elements of water from the functional groups. Moieties containing carboxylic acid groups can be linked with moieties containing carboxylic acid groups to form anhydrides. Moieties containing carboxylic acid groups can be linked to moieties containing alcohols or primary or secondary amines to form esters or amides. Moieties containing hydroxyl groups can be linked to moieties containing hydroxyl or primary or secondary amine groups to form ethers or
substituted amines. Where pluralities of the carboxylic acid, hydroxyl or amine functional groups are contained in one or both antibiotic moieties, linkage will occur but the products may be complex and require chromatographic separation.
DESCRIPTION OF THE INVENTION
Section 1
The present invention describes methods for making a number of linked antibiotic molecules. The linked antibiotics are to be utilized in treating various infections in man and animals, without undue adverse side effects such as toxicity, inflammation and allergies.
There are several groups of these to-be linked compounds which can be enumerated: sulfonamides, penicillins, cephalosporins, quinolones, chloramphenicol, erythryomycin, metronidazole, tetracyclines and aminoglycosides. With each case, the antibiotics to be linked will be taken two at a time from the above groups, thus:
sulfonamide + sulfonamide sulfonamide + penicillin sulfonamide + cephalosporin sulfonamide + quinolone sulfonamide + chloramphenicol sulfonamide + erythromycin sulfonamide + metronidazole sulfonamide + tetracycline sulfonamide + aminoglycoside
penicillin + penicillin penicillin + cephalosporin penicillin + quinolones penicillin + chloramphenicol
penicillin + erythromycin penicillin + metronidazole penicillin + tetracyclines penicillin + aminoglycosides
cephalosporin + cephalosporin cephalosporin + quinolone cephalosporin + chloramphenicol cephalosporin + erythromycin cephalosporin + metronidazole cephalosporin + tetracyclines cephalosporin + aminoglycoside
quinolone + quinolone quinolone + chloramphenicol quinolone + erythromycin quinolone + metronidazole quinolone + tetracyclines quinolone + aminoglycoside
chloramphenicol + chloramphenicol chloramphenicol + erythromycin chloramphenicol + metronidazole chloramphenicol + tetacyclines chloramphenicol + aminoglycoside
erythromycin + erythromycin erythromycin + metronidazole erythromycin + tetracyclines erythromycin + aminoglycoside
metronidazole + metronidazole metronidazole + tetracyclines metronidazole + aminoglycoside
tetracyclines + tetracyclines tetracyclines + aminoglycosides
aminoglycoside + aminoglycoside
Within each of the above groups of antibiotics the members of each to be linked are defined as:
1. Sulfonamides:
A. p-aminobenzenesulfonamide
B. sulfamethoxyazole
D. sulfamethoxypyridazine
E. sulfadiazine
F. trimethoprim
2. Penicillins:
A. benzyl penicillin
C. phenoxymethyl penicillin
D. ampicillin
E. amoxycillin
F. methicillin
H. cloxacillin
I. dicloxacillin
J. flucloxacillin
K. nafcillin
M. ticaricillin
N. talampicillin
O. becampiciUin
0 H3C QCHJCHJ
P. pivampicillin
R. hydroxyethyl penem
S. imipenem
T. amdinocilin
3. Cephalosporins:
A. cephalosporin C
C. cephaloridine
D. cephradine
E. cephazolin
F. cephalexin
H. cefaclor
I. cephamandole
J. cefiiroxine
K. cefotaxime
M. ceftazidime
N. cefoperazone
O. cephamycin C
P. cefoxitin
4. Quinolones:
A. nalidixic acid
B. norfloxacin
C. enoxacin
D. ciprofloxacin
5. Chloramphenicol:
6. Erythromycin:
A. erythromycin
7. Metronidazole:
8. Tetracyclines:
C. chlortetracycline
D. rolitefracyciine
E. methacycline
G. demeclocycline
H. sancycline
I. lymecycline
K. minocycline
9. Aminoglycosides: A streptomycin
B. tobramycin
D. amikacin
E. gentamicin Cl
F. nitilimicin
H. paromomycin
I. spectinomycin
The linking agents that will be used to link the antibiotic moities are drawn from several classes of organic molecules:
I. Diisocyanates and related structures
II. Dianhydrides
III. Diacidchlorides
IV. Diepoxides
V. Dicyclohexylcarbodiimide and related structures The class I linking agents are drawn from the group consisting of the following structures:
I. Diisocyanates and related structures: A. hexamethylene diisocyanate
OCN(CH2)6NCO
B. 2,4-tolyldiisocyanate
D. 4,4 -methylene-bis-phenylisocyanate
E. 4,4'-isopropylidene-bis-phenylisocyanate
G. 1,4-phenyldissocyanate
L fi/J' NC Q
anhydrides:
A. pyromellitic dianhydride
B. bismaleic dianhydride
C. ic anhydride
E. 1,2,5,6-naphthalene tetracarboxylic anhydride
III. Diacidchlorides:
A terphthalolyl dichloride
B. isophthaloyl dichloride
C. pthaloyl dichloride
E. glutaryl chloride
IV. Diepoxides and related structures: A. 1,3-butadiene diepoxide
2 _ o / ^o /
B. cyclooctatetraene diepoxide, 1.5
C. vinyl cyclohexene
V. Carbodumides and related structures: A. Dicyclohexylcarbodiimide
B. Ditolylcarbodiimide
DESCRIPTION OF THE INVENTION Section 2
Methods of Linking Antibiotic Moieties:
The structure of the two antibiotic moieties being linked will determine the nature of the particular linking agent to be employed. Thus when sulfonamides listed above are to be coupeled the basic sulfonamide structure below shows that the group which will be linking the two sulfonamide
structures is the aromatic amino group. Consideration of the entire group of sulfonamides listed above will show that the only reactive group is the aromatic amino group. Of the five linking reagents listed above, four may be employed: diisocyanates, dianhydrides, diacidchlorides, and diepoxides.
The structures which result from coupling sulfonamides with sulfonamides are shown below.
When identical sulfonamides are linked only a single product will result, but obviously when two nonidentical sulfonamides species are linked, three products will result as shown below.
R H fαW l? '
R'H NSi-<g>- NH- £klH - V - NH -f- NH-^ so. NΛ*'
Since, in the experimental section below, equimolar quantities are used in all reactions the mixed products will predominate where the two reacting moieties have diverse structures. The modern methods of liquid chromatography render the separation of such simple mixtures, as above, to be quite simple, thus adequate material can be separated for microbial evaluation tests. Commercial quantities can be separated via preparative scale HPLC (high performance liquid chromatography).
The linking of two antibiotic moieties by utilizing dianhydrides follows a course identical to that described for diisocyanate linking agents, i.e., when a single type moiety is employed, a single product will result, but when two
dissimilar moieties are employed, three products will result. As noted with diisocyanates, separation and evaluation of these products is not difficult.
The linking of two antibiotic moieties utilizing diacid chlorides will pursue a course analagous to the reactions of diisocyanates. When a single antibiotic entity reacts with a diacid chloride a single entity results, but when two different entities react, three products are formed.
Symbolically, the three products can be seen as:
H O O H
I ll II I
A-N-C-Y-C-N-A
H O O H
I II II I A-N-C-Y-C-N-B
H O O H
I II II I
B-N-C-Y-C-N-B
The reaction of two antibiotic moieties with a diepoxide follows a course similar to the diisocyanate reaction with a single moiety resulting in a single product and two moieties resulting in three products, as shown below.
H ϊ Cfc- CH -V- H -CH* + HaN- -WiNH-a.
It will be noted that in the ring opening reaction the attack occurs on carbon #1 in the epoxy group predominantly.
A-NH - CH9 - CH - Y - CH - CH - A 1 I i l
OH OH
A-NH-CH9 -CH-Y-CH9-CH-B
I I
OH OH
B -NH - CH9 - CH - Y - CH - CH - B
OH OH
The above comments with respect to product mix apply to all antibiotic linking reactions occurring with the linking agents diisocyanates, dianhydrides, diacid chlorides, and diepoxides.
The use of the dicarbodumides with antibiotic moieties follows a different pattern. The situation when linking antibiotic moieties via carbodumides is the result of removing the elements of water from two moieties.
Thus the linking of two antibiotic moieties depends upon the presence of the following groups: carboxyl, amino and hydroxyl and requires a minimum total of two such groups, but with a further plurality may also be utilized. The possible combinations of the three reactive groups are five.
O β // // 1. Y-COOH + Y-COOH-^Y-C-O-C-Y
2. Y-COOH + YOH Y-C-O-Y
P /H 3. Y - COOH + YNH2 ) Y- -N-Y
4. Y-OH-YOH ) Y-O-Y
5. Y-OH + YNH2 > Y-N-Y
1
H
The linking of two antibiotic moieties via the groups above produces the following products:
0 O // //
1. anhydride Y-C-O-C-Y
2. ester Y-C A-O-Y
3. amide Y-C A-NH-Y
4. ether Y-O-Y
5. amine Y-NH-Y
When two antibiotics are linked each containing a single reactive group, as one COOH and one NH2, only a single product will result; see the example below of the reaction of dicyclohexylcarbodiimide with p-aminobenzene- sulfonamide with benzylpenicillin.
>
The amide product is easily separated from the by-product dicyclo- hexylurea by crystallization or liquid chromatography techniques.
When more than two active groups are present on a single moiety as penicillin type, carbenicillin, two products will result when linked with p- aminobenzenesulfonamide via dicyclohexylcarbodiimide, as shown below.
+
Rules are developed in the "Rules" section below to account for all products with all linking reagents linking the many antibiotic moieties.
Linking Rules
The linking rules developed below are based on the interactions of the five linking agents with a large number of eight classes of antibiotics.
DESCRIPTION OF THE INVENTION
Section 3
The rules for linking the antibiotic moities are developed by considering all of the above data just concluded for linking all of the individual members of the said eight groups of antibiotics.
The linking rules are as follows:
1. Diisocyanates can react with all acid carboxyl groups, all hydroxyl groups and all primary and secondary amino groups. Thus any antibiotic moiety containing a carboxylic acid group, a hydroxyl group or an amine group, can be linked to any other antibiotic moiety also containing a carboxylic acid group, hydroxyl or amine function.
When a single antibiotic moiety contains a plurality of groups, as a carboxyl group and a hydroxyl group, or a carboxyl group and an amino group, this moiety can be linked by reaction with a diisocyanate to a second antibiotic moiety containing a plurality of groups, as a carboxyl group and a hydroxyl group, or a carboxyl group and an amino group.
When a diisocyanate is utilized to link antibiotic moieties containing a plurality of carboxyl acid, alcohol and amino groups, a mixture of products will be realized, but with chromatographic techniques the mixtures are easily separated.
Summarizing: the diisocyanate reagent can be used to link any two antibiotic moieties each containing at least one carboxylic acid, alcohol or amino functional group, and can also be used when each antibiotic contains a plurality of said groups.
2. Dianhydrides can be utilized to link a wide variety of antibiotic moitieties in which each moiety contains at least one hydroxyl or primary or secondary amine group. The dianhydride reagent can also be utilized to link antibiotic moities in which each moiety contains a multiplicity of hydroxyl or amino groups. In cases involving the linking of antibiotic moities containing a multiplicity of groups, a mix of products will be realized but can be separated easily via chromatographic techniques.
3 Diacidchlorides as a linking agent are covered by rules identical to those for dianhydrides. Diacidchlorides can be used to link a wide variety of antibiotic moieties in which each moiety contains at least one hydroxyl or amino group. The aciddichloride reagent can also be used to link antibiotic moieties where each moiety contains a multiplicity of hydroxyl or and amino groups. In cases involving a multiplicity of groups, a mixture of products will be realized which can be separated easily via chromatographic techniques.
4. Diepoxides as linking agents can be used to link antibiotic moities where each moiety contains a carboxyl, hydroxyl, or amino group, or where each moiety contains a plurality of said groups. When antibiotics possessing a plurality of such groups react with the epoxy linking agents a complex mix of products will be formed which can be separated via chromatographic techniques.
5. Carbodumides as linking agents can be utilized to link a very large number of antibiotic types. Antibiotic moieties in which each moiety
contains a single carboxyl group yield anhydrides. Antibiotic moities in which one moiety contains a carboxyl group only will react with a moiety containing a single hydroxyl group to form a single ester. Antibiotic moieties containing a plurality of carboxyl and hydroxyl groups will form a complex mixture of esters when reacted with carbodumides. Antibiotic moieties containing a single carboxyl group will react with antibiotic moieties containing a single amino group to form a single product containing an amide group. When antibiotic moieties containing a multiplicity of carboxyl, hydroxyl and amino groups are linked via carbodumides, a mixture of esters and amides will be formed. When antibiotic moieties containing singular hydroxyl groups or a multiplicity of hydroxyl groups are linked, the products will be singular or multicomponent ethers. The linking of antibiotic moieties containing singular or multiple hydroxyl and amino groups leads to the formation of a single substituted amine, or a multiplicity of amines. All of the mixtures generated by the above said reactions can be separated via chromatographic techniques.
DESCRIPTION OF THE INVENTION
Section 4
Experimental Procedures
General Comments - The procedures outlined and discussed below describe the experimental procedures necessary to carry out the linking procedures with the many antibiotic moieties previously described in this application.
Procedures for each linking reagent.
Coupling reactions using: 1. Diisocyanates:
Solvents pyridine 50 ml anhydrous
DMAC 50 ml anhydrous
DMF 50 ml anhydrous
N-methylpyrrolidone 50 ml anhydrous
Temperature 0 to 50°C
Time 5-10 hours Quantities 0.01 mole each antibiotic moiety, 0.005 mole of linking reagent
Monitor via IR spectroscopy for -NCO group, 4.45 μ Work-up add water to ppt. product achieve separation of products via chromatography; TLC, column or HPLC.
Evaluation apply to streaked plate of several cultures~E. coli, Strep. Group A, P. aruginosa
Equipment 250 ml round bottom 3-neck flask equipped with glascol mantle for heating, thermometer, reflux condenser and teflon stirring bar energized by magnetic stirring.
Coupling reactions using:
2. Dianhydrides Solvents Same as "1". Temperature Same as \ Time Same as "1".
Quantities Same as "1". Monitor IR via 5.50 and 5.80 anhydride band Work up See l . Evaluation See l.
Coupling reactions utilizing:
3. Diacid chlorides*
All same as 1, but IR monitor via 5.80 acid chloride band in IR
*Prior to the addition of water to terminate the reaction g. (0.25 ml) of sodium bicarbonate is added in small portions to neutralize all hydrochloric acid.
Coupling reactions utilizing:
4. Diepoxides
All same as in 1, but reaction time may be extended to 24 hours to complete reaction. IR monitor via epoxide band at 9.5 μ.
Coupling reactions utilizing: 5. Carbodiimide
All same as 1, but reaction time may be as short as 1 hour. IR monitor is via carbodiimide band at 4.50μ.
Example procedure
1. The reaction p-aminobenzene sulfonamide with sulfapyridine.
The dry pyridine solvent, 50 ml., is placed in the 250 ml round bottom flask and 1.72 g. (0.01 mole) of p-aminobenzenesulfonamide and 1.68 g. (0.01 mole) of hexyldiisocyanate is added, the temperature raised to 40°C by means of the variac controlling the heating of the glascol mantle. The heating and stirring are continued for 4 hours, and at the end of each hour a small sample is withdrawn from the flask by means of a pippette and examined by means of IR sectroscopy. The IR spectrocopy scan is determined from 2.5 microns to 15.0 microns, and the concentration of diisocyanate is determined from the intensity of the absorption band at 4.45 microns, a band due to the -NCO group. A steady drop in the concentration of the -NCO group indicates progress of the reaction. At the end of 4 hours at 40°C the concentration of the isocyanate group has dropped by 80 per cent. The reaction is forced to conclusion by raising the temperature to 50°C for two hours, at the end of which time the -NCO group is not detectable by IR spectroscopy.
The reaction is terminated by the addition of 50 ml of water and the precipitated reaction product dried in a vacuum oven at 25°C for 2 hours to
yield 3.0 g., 8.8 per cent. The product was evaluated for biological activity via applying a 1 per cent solution in pyridine to TLC (thin layer chromatography) plates. The developing solvent used was a 10-90 mixture of acetone and methanol, and the progress was monitored by a UV light. The spots on the chromatogram were evaluated via mechanical removal and the absorbent was separated from the product fraction by dissolving in pyridine, and the pyridine solution was dried onto filter paper. Tabs of the filter paper were applied to ager culture plates streaked with standard bacterial cultures of S. aureus, E. coli and P aureginosa. Standard antibiotics, as p-aminosulfonamide and penicillins were used for comparison. All products showed modest inhibition zones in the vicinity of the filter paper tabs containing the product fractions.
Larger quantities of products are obtainable for animal testing most simply via prep scale liquid chromatography.
Claims
What is claimed is:
An acid anhydride of the formula
O
II
<^>-0-CH2-C // \N - CH - C -
I o
R2 and R^ are:
O O
II /I
o
O
-CH3, NH - C - CH -^ - ° H MH .
O
CH
CH2OCOCH3, NH -
2. A process for preparing the compounds of Claim 1 by reacting a penicillin compound with a cephalosporin compound in the presence of dicyclohexylcarbodiimide in pyridine solution, and isolating the reaction product by means of liquid chromatography and identifying the reaction product by means of IR spectroscopy.
3. A compound of the general formula
where Z is (CH2)n wherein n is 2-20 methylene units and Rj is one of the following groups of antibiotics a) A beta-lactam of the general formula
wherein Y is a side chain containing a pendant amino group;
b) A beta-lactam of the general formula, termed cephalosporin type,
Coo >-J
wherein the molecule contains a six-member sulfur-containing ring, R is H, methyl or carboxyl, and R is a complex side chain always carrying a pendant amine group;
c) A quinolone antibacterial of the general formula wherein
R5 is a carbon or a nitrogen atom and the piperazinyl side-chain carries one free secondary amino group;
d) shown containing
a reactive hydroxyl in the 2" position in the diisoamine portion of the erythromycin molecule; all said antibiotics being linked to chloramphenicol;
4. A process for the preparation of the compounds of Claim 3 by reacting 2,2-dichloro-N-[2-hydroxyl-l-hydroxymethyl-2-(4-nitroρhenyl)ethyl]
acetamide with a penicillin, a cephalosporin, a quinolone and an erythyromycin in the presence of a diacid chloride of the structure
O O,
Cl - C - (CH2)n - C - Cl wherein n is greater than 2 in pyridine solution and isolating the reaction product by means of liquid chromatography and identifying the reaction product by means of IR spectroscopy.
wherein Z is (CH2)n wherein n is 2-20 and Ri is one of the following groups of antibiotics a) A beta-lactam of the penicillin type where Y is a side chain containing a pendant amino group a) r
b) A beta-lactam of the cephalosporin type wherein the molecule contains a 6-membered ring containing sulful, R2 is a methyl, hydrogen or carboxyl group and R3 is a complex side chain carrying one pendant primary amino group,
c) A quinolone antibacterial of the general formula
wherein R5 is a carbon or nitrogen atom and the piperazinyl side- chain carries one free secondary amino group.
6. A process for the preparation of the compounds of Claim 5 by reactioning erythyromvcin with a penicillin, a cephalosporin, and a quinolone in the presence of a diacid chloride, of the structure
wherein n is greater than 2, in pyridine solution and isolating the reaction product by means of liquid chromatography and identifying the reaction product by means of IR spectroscopy.
7. An acid anhydride of the formula
0
in which Rj is equivalent to Rj in Claim 1, and R4 , R5, R^, are respectively
Ethyl, - H, - C = ; Ethyl, H, N = ;
cyclopropyl, H, = C -;
8. A process for the preparation of the compounds of Claim 7 by reacting a penicillin with quinolones in the presence of dicyclohexylcarbodiimide in pyridine solution and isolating the reaction product by means of liquid chromatography and identifying the reaction product by means of IR spectroscopy.
9. A pharmaceutical compound having the following formula
°Z.
where "n" is an integer of 2-12; and where "Z" is selected from the group consi
b)
and
(5
all antibiotic a - e being linked to 2-methyl-5-nitroimidazole-l-ethanol.
10. A process for the preparation of the compounds of Claim 7 by reaction of 2-methyl-5-nitroimidazole-l-ethanol with a penicillin, a cephalosporin, a tetracycline, chloramphenicol, and a quinolone in the presence of a diacid chloride,
O O
Cl - C l - (CH2)n - fc* - Cl wherein n is greater than 2 in pyridine solution and isolating the reaction product by means of liquid chromatography and identifying the reaction product by means of IR spectroscopy.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1997/022012 WO1999028308A1 (en) | 1997-11-29 | 1997-11-29 | Antibiotics and process for preparation |
EP97951517A EP0970065A4 (en) | 1997-11-29 | 1997-11-29 | Antibiotics and process for preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1997/022012 WO1999028308A1 (en) | 1997-11-29 | 1997-11-29 | Antibiotics and process for preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999028308A1 true WO1999028308A1 (en) | 1999-06-10 |
Family
ID=22262179
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/022012 WO1999028308A1 (en) | 1997-11-29 | 1997-11-29 | Antibiotics and process for preparation |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP0970065A4 (en) |
WO (1) | WO1999028308A1 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004005313A2 (en) * | 2002-07-08 | 2004-01-15 | Pliva - Istrazivacki Institut D.O.O. | Hybrid molecules of macrolides with steroid/non-steroid anti-inflammatory, antineoplastic and antiviral active molecules |
US7091196B2 (en) | 2002-09-26 | 2006-08-15 | Rib-X Pharmaceuticals, Inc. | Bifunctional heterocyclic compounds and methods of making and using same |
US7109176B2 (en) | 2002-07-08 | 2006-09-19 | Pliva-Istrazivacki Institut D.O.O. | Nonsteroidal anti-inflammatory substances, compositions and methods for their use |
US8202843B2 (en) | 2004-02-27 | 2012-06-19 | Rib-X Pharmaceuticals, Inc. | Macrocyclic compounds and methods of making and using the same |
US8906898B1 (en) | 2013-09-27 | 2014-12-09 | Calixa Therapeutics, Inc. | Solid forms of ceftolozane |
US8968753B2 (en) | 2013-03-15 | 2015-03-03 | Calixa Therapeutics, Inc. | Ceftolozane-tazobactam pharmaceutical compositions |
US9044485B2 (en) | 2013-03-15 | 2015-06-02 | Calixa Therapeutics, Inc. | Ceftolozane antibiotic compositions |
CN106124683A (en) * | 2016-08-26 | 2016-11-16 | 中国兽医药品监察所 | A kind of method of multiple antimicrobial component in veterinary drug of detection simultaneously |
US9724353B2 (en) | 2011-09-09 | 2017-08-08 | Merck Sharp & Dohme Corp. | Methods for treating intrapulmonary infections |
US9872906B2 (en) | 2013-03-15 | 2018-01-23 | Merck Sharp & Dohme Corp. | Ceftolozane antibiotic compositions |
US10232345B2 (en) | 2015-02-12 | 2019-03-19 | Arizona Board Of Regents On Behalf Of Arizona State University | Aminoglycoside hydrogel microbeads and macroporous gels with chemical crosslink, method of preparation and use thereof |
US10376496B2 (en) | 2013-09-09 | 2019-08-13 | Merck, Sharp & Dohme Corp. | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4837311A (en) * | 1987-06-22 | 1989-06-06 | Hoffman-La Roche Inc. | Anti-retroviral compounds |
US5180719A (en) * | 1988-10-24 | 1993-01-19 | Norwich Eaton Pharmaceuticals, Inc. | Antimicrobial quinolonyl lactam esters |
ES2101119T3 (en) * | 1991-10-01 | 1997-07-01 | Procter & Gamble Pharma | PROCEDURE FOR PREPARING QUINOLONIL-ANTIMICROBIAL LACTAMS. |
US5693791A (en) * | 1995-04-11 | 1997-12-02 | Truett; William L. | Antibiotics and process for preparation |
-
1997
- 1997-11-29 EP EP97951517A patent/EP0970065A4/en not_active Withdrawn
- 1997-11-29 WO PCT/US1997/022012 patent/WO1999028308A1/en not_active Application Discontinuation
Non-Patent Citations (3)
Title |
---|
CHEMICAL ABSTRACTS, Vol. 113, No. 130724, (Columbus, Ohio, USA), KURODA, "Manufacture of Cephalosporins with Penicillin G Amidase"; & JP 2138188 A (28-05-90). * |
CHEMICAL ABSTRACTS, Vol. 120, No. 293945, 1994, (Columbus, Ohio, USA), PAGE, MALCOLM G.P., "The Reaction of Cephalosporins with Penicillin-Binding Protein LB.gamma. from Escherichia Coli"; & BIOCHIM. BIOPHYS. ACTA, 1994, 1205(2), 199-206 (Eng). * |
See also references of EP0970065A4 * |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004005313A2 (en) * | 2002-07-08 | 2004-01-15 | Pliva - Istrazivacki Institut D.O.O. | Hybrid molecules of macrolides with steroid/non-steroid anti-inflammatory, antineoplastic and antiviral active molecules |
WO2004005313A3 (en) * | 2002-07-08 | 2005-04-21 | Pliva Istrazivacki Inst D O O | Hybrid molecules of macrolides with steroid/non-steroid anti-inflammatory, antineoplastic and antiviral active molecules |
US7109176B2 (en) | 2002-07-08 | 2006-09-19 | Pliva-Istrazivacki Institut D.O.O. | Nonsteroidal anti-inflammatory substances, compositions and methods for their use |
US7157433B2 (en) | 2002-07-08 | 2007-01-02 | Glaxosmithkline Istrazivacki Centar Zagreb | Compounds, compositions as carriers for steroid/nonsteroid anti-inflammatory; antienoplastic and antiviral active molecules |
US7091196B2 (en) | 2002-09-26 | 2006-08-15 | Rib-X Pharmaceuticals, Inc. | Bifunctional heterocyclic compounds and methods of making and using same |
US7335753B2 (en) | 2002-09-26 | 2008-02-26 | Rib-X Pharmaceuticals, Inc. | Bifunctional heterocyclic compounds and methods of making and using same |
US8202843B2 (en) | 2004-02-27 | 2012-06-19 | Rib-X Pharmaceuticals, Inc. | Macrocyclic compounds and methods of making and using the same |
US8841263B2 (en) | 2004-02-27 | 2014-09-23 | Melinta Therapeutics, Inc. | Macrocyclic compounds and methods of making and using the same |
US10028963B2 (en) | 2011-09-09 | 2018-07-24 | Merck Sharp & Dohme Corp. | Methods for treating intrapulmonary infections |
US9724353B2 (en) | 2011-09-09 | 2017-08-08 | Merck Sharp & Dohme Corp. | Methods for treating intrapulmonary infections |
US8968753B2 (en) | 2013-03-15 | 2015-03-03 | Calixa Therapeutics, Inc. | Ceftolozane-tazobactam pharmaceutical compositions |
US9044485B2 (en) | 2013-03-15 | 2015-06-02 | Calixa Therapeutics, Inc. | Ceftolozane antibiotic compositions |
US9320740B2 (en) | 2013-03-15 | 2016-04-26 | Merck Sharp & Dohme Corp. | Ceftolozane-tazobactam pharmaceutical compositions |
US9872906B2 (en) | 2013-03-15 | 2018-01-23 | Merck Sharp & Dohme Corp. | Ceftolozane antibiotic compositions |
US10420841B2 (en) | 2013-03-15 | 2019-09-24 | Merck, Sharp & Dohme Corp. | Ceftolozane antibiotic compositions |
US11278622B2 (en) | 2013-03-15 | 2022-03-22 | Merck Sharp & Dohme Corp. | Ceftolozane antibiotic compositions |
US10376496B2 (en) | 2013-09-09 | 2019-08-13 | Merck, Sharp & Dohme Corp. | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function |
US10933053B2 (en) | 2013-09-09 | 2021-03-02 | Merck Sharp & Dohme Corp. | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function |
US8906898B1 (en) | 2013-09-27 | 2014-12-09 | Calixa Therapeutics, Inc. | Solid forms of ceftolozane |
US10232345B2 (en) | 2015-02-12 | 2019-03-19 | Arizona Board Of Regents On Behalf Of Arizona State University | Aminoglycoside hydrogel microbeads and macroporous gels with chemical crosslink, method of preparation and use thereof |
CN106124683A (en) * | 2016-08-26 | 2016-11-16 | 中国兽医药品监察所 | A kind of method of multiple antimicrobial component in veterinary drug of detection simultaneously |
Also Published As
Publication number | Publication date |
---|---|
EP0970065A4 (en) | 2001-03-07 |
EP0970065A1 (en) | 2000-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5693791A (en) | Antibiotics and process for preparation | |
EP0970065A1 (en) | Antibiotics and process for preparation | |
PL127434B1 (en) | Method of obtaining new methanodiole diesters with with penicillines and 1,1-penicillatic acid dioxide | |
CN1918172B (en) | Rifamycin analogs and uses thereof | |
KR860001279B1 (en) | Process for crystalline benzensulfonate salts of sultamicillin | |
NL8000775A (en) | BETA-LACTAM COMPOUNDS AND MEDICINES BASED THEREOF. | |
US3935204A (en) | Cephalosporin and pharmaceutical preparations containing the same | |
US4117221A (en) | Aminoacyl derivatives of aminoglycoside antibiotics | |
Ertan et al. | Synthesis and biological evaluation of new N-(2-hydroxy-4 (or 5)-nitro/aminophenyl) benzamides and phenylacetamides as antimicrobial agents | |
OHI et al. | Semisynthetic β-lactam antibiotics I. Synthesis and antibacterial activity of new ureidopenicillin derivatives having catechol moieties | |
McKee et al. | Iron transport mediated drug delivery systems: synthesis and antibacterial activity of spermidine-and lysine-based siderophore-. beta.-lactam conjugates | |
US4837206A (en) | Esperamicin derivatives | |
GB2030141A (en) | Novel aminoglycosides, their production and use as anti-microbial agents | |
Dunn et al. | Orally active 7-phenylglycyl cephalosporins structure-activity studies related to cefatrizine (SK&F 60771) | |
US3706746A (en) | O-desacetyl derivatives of 7-n-acylamino-cephalosphoranic acids | |
Thu et al. | Synthesis and antibacterial evaluation of new monobactams | |
GB2178740A (en) | Alkylcarbamoyloxymethylcephem compounds | |
AU2009322925A1 (en) | Novel semi-synthetic glycopeptides as antibacterial agents | |
IE50057B1 (en) | Paromomycin derivatives | |
US6013647A (en) | Benzoxazinedione derivatives, method of producing them and uses thereof | |
US4358585A (en) | 5-Deoxyapramycin | |
CN106032367B (en) | Chinese cymbidium amine/chinese cymbidium 01 derivatives and its preparation method and application | |
EP0048613B1 (en) | 4-0-substituted -2-deoxystreptamine aminoglycoside derivatives, their preparation and formulations containing them | |
PL110876B1 (en) | Process for the preparation of novel 7beta-/d-2-amine-2-/r'-sulfonylaminephenyl/-acetylamine/-3-r-3-cephem-4-carboxylic acids | |
EP0048614B1 (en) | 1-n-acylated and 1-n-alkylated derivatives of 4-0-substituted -2-deoxystreptamine aminoglycosides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1997951517 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1997951517 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997951517 Country of ref document: EP |